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Update on Avian Influenza A (H5N1)
This update reviews 1) the current epidemiologic situation in Asia and 2) the U.S. surveillance, laboratory 
diagnostic, and infection control recommendations for avian influenza A (H5N1), which were most recently stated 
in August 2004. As detailed in the recommendations below, identification of possible imported cases of avian 
influenza A (H5N1) in the U.S. clinical setting depends on health-care providers consistently obtaining information 
on recent international travel and other potential exposures from persons who have certain respiratory symptoms.
Current Situation
Outbreaks of avian influenza A (H5N1) among poultry are ongoing in several countries in Asia, including Thailand, 
Vietnam, and Cambodia. Reports of sporadically occurring human cases of influenza A (H5N1) continued through 
January 2005. Thailand reported five human cases of influenza H5N1 (with four deaths) in September and 
October 2004, but no additional cases to date. Thirteen human cases of influenza A (H5N1) infection (with 12 
deaths) have been reported by Vietnam since mid-December 2004; WHO has reported that 10 of these cases 
(with 9 deaths) have been confirmed.
One instance of probable limited human-to-human transmission of influenza A (H5N1) virus was reported in 
Thailand between a child and her mother and aunt in September 2004. Health authorities in Vietnam are 
investigating two possible instances of limited human-to-human transmission in family clusters. One instance 
involves two brothers in Vietnam with confirmed influenza A (H5N1) infections; a third brother was hospitalized for 
observation only and did not become ill. In the second instance, a daughter developed symptoms within 6 days of 
her mother's onset of illness, which was confirmed as influenza A (H5N1). Investigations are exploring possible 
sources of exposure and looking for other signs of illness in family members, other close contacts, and the 
general community.
In addition, the first human case of influenza H5 infection in Cambodia has been confirmed in a woman who was 
hospitalized in Vietnam and died. A joint mission between the Cambodian Ministries of Health and Agriculture and 
WHO is in Cambodia investigating the circumstances surrounding this case.
As of February 4, 2005, the cumulative number of confirmed human cases of influenza A (H5N1) reported in Asia 
since January 28, 2004, is 55 cases (with 42 deaths), according to WHO. This total includes the case from 
Cambodia.
The avian influenza A (H5N1) epizootic in Asia poses an important public health threat, and CDC is in 
communication with WHO and will continue to monitor the situation. The epizootic in Asia is not expected to 
diminish substantially in the short term, and it is likely that influenza A (H5N1) infection among birds has become 
endemic to the region and that human infections will continue to occur. So far, no sustained human-to-human
transmission of the influenza A (H5N1) virus has been identified, and no influenza A (H5N1) viruses containing 
both human and avian influenza virus genes, indicative of gene reassortment, have been detected.
Travel Health Precaution
It is expected that the number of people traveling between the United States and certain parts of Asia will 
increase around the Lunar New Year, which occurs on February 9 this year. Chinese, Vietnamese, Cambodian, 
and Korean people celebrate the start of the lunar calendar year. Lunar New Year celebrations last for 
approximately 15 days in China, 3 days in Vietnam, and typically only 1 day in Cambodia and Korea.
On January 26, 2005, CDC issued a Travel Health Precaution notice about avian influenza A (H5N1). This notice 
is directed at travelers who may be returning from Vietnam to visit family and friends, especially during the 
upcoming holiday, and who may be at greater risk for exposure to poultry through food preparation or at farms 
and bird markets where infected poultry may not be readily detected. The notice outlines specific measures for 
travelers to take before, during, and after travel to Vietnam. CDC has not recommended that the general public 
avoid travel to any countries affected by influenza A (H5N1). For more information, see CDC's Travelers' Health 
website.
Enhanced U.S. Surveillance, Diagnostic Evaluation, and Infection Control Precautions for Avian Influenza 
A (H5N1)
CDC recommends maintaining the enhanced surveillance efforts by state and local health departments, hospitals, 
and clinicians to identify patients at increased risk for avian influenza A (H5N1) as described in HAN notices that 
were issued on February 3, 2004 and again on August 12, 2004. Guidelines for enhanced surveillance are as 
follows.
Testing for avian influenza A (H5N1) is indicated for hospitalized patients with
• radiographically confirmed pneumonia, acute respiratory distress syndrome (ARDS), or other severe
respiratory illness for which an alternate diagnosis has not been established, AND
• history of travel within 10 days of symptom onset to a country with documented H5N1 avian influenza in
poultry and/or humans (for a regularly updated listing of H5N1-affected countries, see the OIE 
website and the WHO website).
Testing for avian influenza A (H5N1) should be considered on a case-by-case basis in consultation with state and
local health departments for hospitalized or ambulatory patients with:
• documented temperature of >38°C (>100.4°F), AND
• one or more of the following: cough, sore throat, shortness of breath, AND
• history of contact with poultry (e.g., visited a poultry farm, a household raising poultry, or a bird market)
or a known or suspected human case of influenza A (H5N1) in an H5N1-affected country within 10 
days of symptom onset.
Laboratory Testing Procedures
Virus Culture
Highly pathogenic avian influenza A (H5N1) is classified as a select agent, and culturing of clinical specimens for 
influenza A (H5N1) virus must be conducted under laboratory conditions that meet the requirements for Biosafety 
Level (BSL) 3 with enhancements. These enhancements include controlled access double-door entry with change 
room and shower, use of respirators, decontamination of all wastes, and showering out of all personnel. 
Laboratories working on these viruses must be certified by the U.S. Department of Agriculture. CDC recommends 
that virus isolation studies be conducted on respiratory specimens from patients who meet the above criteria only 
if requirements for BSL 3 with enhancements can be met.
Polymerase Chain Reaction (PCR) and Commercial Antigen Testing
Clinical specimens from suspect influenza A (H5N1) cases may be tested by PCR assays under standard BSL 2 
conditions in a Class II biological safety cabinet. In addition, commercial antigen detection testing can be 
conducted under standard BSL 2 conditions used to test for influenza.
Specimens That Should Be Sent to CDC
Specimens from persons meeting the above clinical and epidemiologic criteria should be sent to CDC if
• The specimen tests positive for influenza A virus by PCR or by antigen detection testing, OR
• PCR assays for influenza are not available at the state public health laboratory.
CDC also will accept specimens from persons meeting the above clinical criteria even if they test negative by 
influenza rapid diagnostic testing if PCR assays are not available at the state laboratory. This is because the 
sensitivity of commercially available rapid diagnostic tests for influenza may not always be optimal.
Requests for testing should come through the state and local health departments, which should contact (404) 
639-3747 or (404) 639-3591 and ask for the epidemiologist on call before sending specimens to CDC for 
influenza A (H5N1) testing.
Interim Recommendations: Infection Control Precautions for Influenza A (H5N1)
Infection control precautions for H5N1 remain unchanged from the CDC interim recommendations issued on 
February 3, 2004. All patients who present to a health-care setting with fever and respiratory symptoms should be 
managed according to recommendations for Respiratory Hygiene and Cough Etiquette and questioned regarding 
their recent travel history. Isolation precautions identical to those recommended for SARS should be implemented 
for all hospitalized patients diagnosed with or under evaluation for influenza A (H5N1) as follows:
• Standard Precautions
o Pay careful attention to hand hygiene before and after all patient contact
• Contact Precautions
o Use gloves and gown for all patient contact
• Eye protection
o Wear when within 3 feet of the patient
• Airborne Precautions
o Place the patient in an airborne isolation room (i.e., monitored negative air pressure in relation 
to the surrounding areas with 6 to 12 air changes per hour).
o Use a fit-tested respirator, at least as protective as a NIOSH-approved N-95 filtering facepiece 
respirator, when entering the room.
For additional information regarding these and other health-care isolation precautions, see the Guidelines for 
Isolation Precautions in Hospitals. These precautions should be continued for 14 days after onset of symptoms 
until an alternative diagnosis is established or until diagnostic test results indicate that the patient is not infected 
with influenza A virus (see Laboratory Testing Procedures below). Patients managed as outpatients or 
hospitalized patients discharged before 14 days should be isolated in the home setting on the basis of principles 
outlined for the home isolation of SARS patients (see http://www.cdc.gov/ncidod/sars/guidance/i/pdf/i.pdf).
Additional Avian Influenza A (H5N1) Information
• For information about reported outbreaks of avian influenza A (H5N1) among poultry, see the website of
the World Organization of Animal Health (OIE).
• For information about human influenza A (H5N1) cases, see the WHO website.
• For clinical information about human influenza A (H5N1) cases, see:
o CDC. Cases of influenza A (H5N1) - Thailand, 2004. MMWR 2004;53:100-103.
o Hien TT, Liem AT, Dung NT, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. New 
England Journal of Medicine 2004;350:1179-1188.
• For information about travel and avian H5N1 influenza, see the CDC Travelers' Health website.
• For general information about influenza, see the CDC Influenza website.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national and international
organizations.
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